BR112017020894A2 - imunoreceptores específicos claudina-18.2 e epítopos de células t - Google Patents

imunoreceptores específicos claudina-18.2 e epítopos de células t

Info

Publication number
BR112017020894A2
BR112017020894A2 BR112017020894A BR112017020894A BR112017020894A2 BR 112017020894 A2 BR112017020894 A2 BR 112017020894A2 BR 112017020894 A BR112017020894 A BR 112017020894A BR 112017020894 A BR112017020894 A BR 112017020894A BR 112017020894 A2 BR112017020894 A2 BR 112017020894A2
Authority
BR
Brazil
Prior art keywords
claudin
cell epitopes
immunoreceptors
specific immunoreceptors
specific
Prior art date
Application number
BR112017020894A
Other languages
English (en)
Inventor
Breitkreuz Andrea
Anna Mroz Karolina
HEBICH Lisa
Simon Petra
Omokoko Tana
Sahin Ugur
Tureci Özlem
Original Assignee
Biontech Cell & Gene Therapies Gmbh
Tron ? Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53181285&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112017020894(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biontech Cell & Gene Therapies Gmbh, Tron ? Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh filed Critical Biontech Cell & Gene Therapies Gmbh
Publication of BR112017020894A2 publication Critical patent/BR112017020894A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Abstract

a presente invenção fornece imunorreceptores específicos de claudin-18.2 (receptores de células t e receptores artificiais de células t (receptores de antígenos quiméricos, car)) e epítopos de células t que são úteis para imunoterapia.
BR112017020894A 2015-05-11 2016-05-09 imunoreceptores específicos claudina-18.2 e epítopos de células t BR112017020894A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2015/060357 WO2016180468A1 (en) 2015-05-11 2015-05-11 Claudin-18.2-specific immunoreceptors and t cell epitopes
PCT/EP2016/060337 WO2016180782A1 (en) 2015-05-11 2016-05-09 Claudin-18.2-specific immunoreceptors and t cell epitopes

Publications (1)

Publication Number Publication Date
BR112017020894A2 true BR112017020894A2 (pt) 2018-07-10

Family

ID=53181285

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017020894A BR112017020894A2 (pt) 2015-05-11 2016-05-09 imunoreceptores específicos claudina-18.2 e epítopos de células t

Country Status (20)

Country Link
US (2) US11713346B2 (pt)
EP (3) EP3795177B1 (pt)
JP (3) JP6942059B2 (pt)
KR (2) KR102409948B1 (pt)
CN (2) CN115109141A (pt)
AU (2) AU2016259730B2 (pt)
BR (1) BR112017020894A2 (pt)
CA (1) CA2982422C (pt)
DK (2) DK3294333T3 (pt)
ES (2) ES2921801T3 (pt)
HK (2) HK1247815A1 (pt)
HR (1) HRP20220799T1 (pt)
HU (2) HUE059282T2 (pt)
LT (1) LT3795177T (pt)
MX (2) MX2017014193A (pt)
PL (2) PL3294333T3 (pt)
PT (2) PT3795177T (pt)
RS (1) RS63380B1 (pt)
SI (2) SI3294333T1 (pt)
WO (2) WO2016180468A1 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105315375B (zh) 2014-07-17 2021-04-23 恺兴生命科技(上海)有限公司 靶向cld18a2的t淋巴细胞及其制备方法和应用
WO2016180468A1 (en) 2015-05-11 2016-11-17 Biontech Cell & Gene Therapies Gmbh Claudin-18.2-specific immunoreceptors and t cell epitopes
WO2018181207A1 (ja) * 2017-03-27 2018-10-04 ノイルイミューン・バイオテック株式会社 キメラ抗原受容体
MX2020008390A (es) * 2018-02-11 2020-12-07 Memorial Sloan Kettering Cancer Center Receptores de linfocitos t no restringidos a antígenos leucocitarios humanos (hla) y usos de los mismos.
MX2020009326A (es) * 2018-03-08 2020-10-08 Phanes Therapeutics Inc Anticuerpos anti-claudina 18.2 y usos de los mismos.
KR20210013013A (ko) * 2018-03-09 2021-02-03 카르스젠 테라퓨틱스 리미티드 종양 치료 방법 및 조성물
KR102340989B1 (ko) * 2018-03-28 2021-12-20 에이비온 주식회사 클라우딘 3의 ecl-2에 특이적으로 결합하는 항체, 이의 단편 및 이들의 용도
WO2019242505A1 (zh) * 2018-06-17 2019-12-26 上海健信生物医药科技有限公司 靶向cldn18.2的抗体、双特异性抗体、adc和car及其应用
WO2020038404A1 (zh) * 2018-08-22 2020-02-27 瑞阳(苏州)生物科技有限公司 抗人claudin 18.2单克隆抗体及其应用
CN110862454B (zh) * 2018-08-27 2022-12-30 南京圣和药业股份有限公司 一种抗Claudin18_2抗体及其应用
BR112021003799A2 (pt) * 2018-08-31 2021-05-18 Invectys SA método para avaliar a funcionalidade de car
JP7401538B2 (ja) * 2018-10-22 2023-12-19 シャンハイ、ケンパーソー、バイオテクノロジー、カンパニー、リミテッド 抗ｃｌｄｎ１８．２抗体およびその使用
CA3116749A1 (en) * 2018-10-24 2020-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hla-a3-restricted t cell receptors against mutated ras
JP2022515487A (ja) * 2018-12-28 2022-02-18 ナンジン、ジェンスクリプト、バイオテック、カンパニー、リミテッド クローディン１８．２結合部分およびその利用
JP2022524906A (ja) * 2019-01-07 2022-05-11 クレージュ メディカル カンパニー，リミテッド 細胞免疫療法の組み合わせ
CN114106183B (zh) 2019-01-15 2023-06-23 浙江道尔生物科技有限公司 抗cld18a2纳米抗体及其应用
CN109762067B (zh) * 2019-01-17 2020-02-28 北京天广实生物技术股份有限公司 结合人Claudin 18.2的抗体及其用途
SG11202109052YA (en) * 2019-03-29 2021-10-28 Phanes Therapeutics Inc Humanized anti-claudin 18.2 chimeric antigen receptors and uses thereof
WO2020239005A1 (zh) * 2019-05-30 2020-12-03 山东博安生物技术有限公司 靶向Claudin18.2的抗体或嵌合抗原受体
CN116063504A (zh) * 2019-07-12 2023-05-05 明济生物制药（北京）有限公司 Cldn18.2抗体及其用途
BR112022003147A2 (pt) * 2019-08-20 2022-05-17 Suzhou Transcenta Therapeutics Co Ltd Novos anticorpos anti-cldn18.2
WO2021047599A1 (en) * 2019-09-13 2021-03-18 Beijing Xuanyi Pharmasciences Co., Ltd. Humanized anti-claudin 18.2 (cldn18.2) antibodies
WO2021238831A1 (en) * 2020-05-25 2021-12-02 Mabspace Biosciences (Suzhou) Co., Limited Anti-cldn18.2 antibodies and diagnostic uses thereof
CN114222761B (zh) * 2020-07-14 2024-02-20 浙江道尔生物科技有限公司 一种抗cld18a2的单域抗体
CN117229398A (zh) * 2022-06-15 2023-12-15 中山康方生物医药有限公司 抗cldn18.2抗体、其药物组合物及用途
CN116751302B (zh) * 2023-08-03 2023-11-10 中国人民解放军军事科学院军事医学研究院 靶向Claudin18.2的抗体、衍生产品及其在肿瘤治疗中的应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677139A (en) 1995-04-21 1997-10-14 President And Fellows Of Harvard College In vitro differentiation of CD34+ progenitor cells into T lymphocytes
WO1997024447A1 (en) 1996-01-02 1997-07-10 Chiron Corporation Immunostimulation mediated by gene-modified dendritic cells
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
DE102004024617A1 (de) * 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
DK1753783T3 (en) * 2004-06-03 2014-11-17 Novlmmune Sa Anti-CD3 antibodies, and methods of use thereof
EP1790664A1 (en) * 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
JPWO2008146672A1 (ja) 2007-05-23 2010-08-19 三菱電機株式会社 エスカレータ用照明兼搭乗者転倒検知システム、エスカレータ用照明兼省エネルギー向け搭乗者有無検知システム及びエスカレータ用照明兼搭乗者利用状況検知システム
EP1997832A1 (en) * 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Monoclonal antibodies against Claudin-18 for treatment of cancer
JP6199036B2 (ja) * 2010-03-16 2017-09-20 バイオエヌテック アーゲーＢｉｏＮＴｅｃｈ ＡＧ 自己タンパク質に対する体液性免疫応答に関わる腫瘍ワクチン接種
US9586997B2 (en) * 2010-09-20 2017-03-07 Biontech Cell & Gene Therapies Gmbh Antigen-specific T cell receptors and T cell epitopes
JP6053688B2 (ja) 2011-10-07 2016-12-27 国立大学法人三重大学 キメラ抗原受容体
WO2013167153A1 (en) * 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
WO2013174403A1 (en) * 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
JP6499079B2 (ja) 2012-11-13 2019-04-10 バイオエヌテック アーゲーＢｉｏＮＴｅｃｈ ＡＧ クローディンを発現するガン疾患を処置するための剤
WO2014146672A1 (en) * 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Therapy involving antibodies against claudin 18.2 for treatment of cancer
EP3039040B1 (en) * 2013-08-26 2021-12-22 Hinrich Abken Anti cd30 chimeric antigen receptor and its use
ES2699753T3 (es) * 2014-01-29 2019-02-12 Biontech Ag Mimótopos peptídicos de claudina 18.2 y sus usos
PT3126381T (pt) 2014-04-01 2019-04-18 Ganymed Pharmaceuticals Ag Imunorrecetores e epítopos de células t específicos da claudina-6
CN105315375B (zh) * 2014-07-17 2021-04-23 恺兴生命科技(上海)有限公司 靶向cld18a2的t淋巴细胞及其制备方法和应用
WO2016123143A1 (en) * 2015-01-26 2016-08-04 The University Of Chicago CAR T-CELLS RECOGNIZING CANCER-SPECIFIC IL 13Rα2
WO2016180468A1 (en) 2015-05-11 2016-11-17 Biontech Cell & Gene Therapies Gmbh Claudin-18.2-specific immunoreceptors and t cell epitopes

Also Published As

Publication number Publication date
EP3795177B1 (en) 2022-04-13
JP7194230B2 (ja) 2022-12-21
SI3795177T1 (sl) 2022-08-31
HK1247815A1 (zh) 2018-10-05
KR20220084208A (ko) 2022-06-21
JP2018524273A (ja) 2018-08-30
HUE059282T2 (hu) 2022-11-28
EP3795177A1 (en) 2021-03-24
KR102409948B1 (ko) 2022-06-21
PT3294333T (pt) 2020-11-25
WO2016180782A8 (en) 2017-11-09
US20230303656A1 (en) 2023-09-28
JP2021153589A (ja) 2021-10-07
AU2016259730A8 (en) 2017-11-02
AU2016259730A1 (en) 2017-10-19
EP3294333A1 (en) 2018-03-21
HRP20220799T1 (hr) 2022-10-14
US20180282389A1 (en) 2018-10-04
LT3795177T (lt) 2022-08-10
HK1250331A1 (zh) 2018-12-14
NZ735850A (en) 2022-03-25
EP4082565A1 (en) 2022-11-02
AU2020257113A1 (en) 2020-11-19
PL3294333T3 (pl) 2021-03-08
KR20170140266A (ko) 2017-12-20
CN107960056A (zh) 2018-04-24
US11713346B2 (en) 2023-08-01
PL3795177T3 (pl) 2022-08-08
CN115109141A (zh) 2022-09-27
AU2020257113B2 (en) 2022-12-01
RS63380B1 (sr) 2022-08-31
MX2017014193A (es) 2018-03-28
WO2016180468A1 (en) 2016-11-17
AU2016259730B2 (en) 2020-11-05
HUE052961T2 (hu) 2021-06-28
SI3294333T1 (sl) 2021-03-31
MX2022000132A (es) 2022-02-16
ES2835269T3 (es) 2021-06-22
ES2921801T3 (es) 2022-08-31
DK3795177T3 (da) 2022-07-04
DK3294333T3 (da) 2020-11-23
EP3294333B1 (en) 2020-09-02
CA2982422C (en) 2023-11-28
WO2016180782A1 (en) 2016-11-17
JP2023039980A (ja) 2023-03-22
CA2982422A1 (en) 2016-11-17
CN107960056B (zh) 2022-07-12
PT3795177T (pt) 2022-07-12
JP6942059B2 (ja) 2021-09-29

Similar Documents

Publication Publication Date Title
BR112017020894A2 (pt) imunoreceptores específicos claudina-18.2 e epítopos de células t
BR112016022727A2 (pt) ?imunorreceptores específicos de claudina-6 e epítopos de células t
CL2018001556A1 (es) Receptores de antígenos quiméricos (car) de bcma. (solicitud divisional 201701515)
CL2020000938A1 (es) Anticuerpos anti-tigit, sus composiciones y uso. (divisional solicitud 201800744)
CY1125032T1 (el) Υποκινητης mnd χιμαιρικους υποδοχεις αντιγονου
CL2019001224A1 (es) Composiciones de células t con car anti--bcma.
CO2017006740A2 (es) Anticuerpos anti–cd79b
PH12018500861A1 (en) Antibody/t-cell receptor chimeric constructs and uses thereof
CO2018011364A2 (es) Anticuerpos anti-il-33, composiciones, métodos y usos de los mismos
MX2020009649A (es) Anticuerpos monoclonales contra bcma.
CL2017000278A1 (es) Moléculas biespecíficas de unión a antígeno activadoras de células t
BR112017007170A2 (pt) anticorpos anti-ox40 humanizados e suas utilizações
CO2018000244A2 (es) Anticuerpos madurados por afinidad y humanizados para fcrh5
PH12017500861A1 (en) Anti-interleukin-33 antibodies and uses thereof
CL2017000590A1 (es) Anticuerpos anti-cll-1 e inmunoconjugados
CR20170131A (es) Anticuerpos anti-her2 e inmunoconjugados
BR112017020054A2 (pt) anticorpos para icos
BR112017023943A2 (pt) anticorpos heterodimêricos que ligam cd3 e antígenos de tumor
NZ736728A (en) Cd123 antibodies and conjugates thereof
MX2017000419A (es) Anticuerpos anti-pd-l1 y sus usos de diagnóstico.
SG10201900455YA (en) Bcma chimeric antigen receptors
BR112017022838A2 (pt) receptores quiméricos de antígeno de antígenos de mieloma kappa e seus usos
BR112018006991A2 (pt) receptores de antígeno quiméricos direcionados ao psca
MX2023006416A (es) Anticuerpos, usos y metodos.
ZA201800804B (en) Novel anti-human gpvi antibodies and uses thereof

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]